Previous 10 | Next 10 |
home / stock / lly / lly articles
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL Int...
Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NY...
On Wednesday, Eli Lilly And Co (NYSE:LLY) announced that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity...
On Monday, Structure Therapeutics Inc. (NASDAQ:GPCR) revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290. In the Phase ...
On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. (NYSE:LLY). QurAlis has grant...
Novo Nordisk A/S (NYSE:NVO) has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling p...
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and...
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (ARCA:IYH), ...
Goldman Sachs analysts re-rated Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), citing the potential for their weight-loss drugs. The ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...
2024-07-02 16:00:05 ET Terence Flynn from Morgan Stanley issued a price target of $1,023.00 for LLY on 2024-07-02 14:30:00. The adjusted price target was set to $1,023.00. At the time of the announcement, LLY was trading at $906.1521. The overall price target consensus i...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participan...